



# DURECT Corporation to Announce Second Quarter 2021 Financial Results and Provide Business Update on July 29

CUPERTINO, Calif., July 22, 2021 /PRNewswire/ — [DURECT Corporation](#) (Nasdaq: DRRX) today announced that it will report its second quarter 2021 financial results and host a conference call after the market close on Thursday, July 29, 2021.

***Thursday, July 29 @ 4:30pm Eastern Time / 1:30 p.m. Pacific Time***

Toll Free: 877-407-0784  
International: 201-689-8560  
Conference ID: 13721980  
Webcast: <http://public.viavid.com/index.php?id=145979>

## **About DURECT Corporation**

DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DUR-928, the company's lead drug candidate is in clinical development for the potential treatment of alcohol-associated hepatitis (AH) for which FDA has granted a Fast Track Designation. The Company is conducting a double-blind, placebo-controlled Phase 2b clinical trial called AHFIRM, evaluating DUR-928's life saving potential compared to the current standard of care in patients with severe AH. Non-alcoholic steatohepatitis (NASH) is also being explored. In addition, POSIMIR<sup>®</sup> (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER<sup>®</sup> platform technology, is now FDA-approved. Full prescribing information about POSIMIR, including the Boxed Warning, can be found at [www.posimir.com](http://www.posimir.com). For more information about DURECT, please visit [www.durect.com](http://www.durect.com) and follow us on Twitter <https://twitter.com/DURECTCorp>.

## **DURECT Forward-Looking Statement**

The statements in this press release regarding the potential for DUR-928 to treat patients with AH, NASH, and other diseases, multiple acute organ injury, ongoing and planned clinical trials of DUR-928, and the commercial potential of POSIMIR are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risks that the clinical trial of DUR-928 in AH takes longer to conduct than anticipated due to COVID-19 or other factors, the risk that clinical trials of DUR-928, including AHFIRM, do not confirm the results from earlier clinical or pre-clinical trials, or do not demonstrate the safety or efficacy or the life saving potential of DUR-928 in a statistically significant manner, risks that we or a third-party licensee may not commercialize POSIMIR successfully, if at all, and risks related to our ability to obtain capital to fund operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-K filed on March 5, 2021 under the heading "Risk Factors."

NOTE: POSIMIR<sup>®</sup> and SABER<sup>®</sup> are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. DUR-928 is an investigational drug candidate under development and has not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities for any indication. Full prescribing information for POSIMIR, including its Boxed Warning, can be found at [www.posimir.com](http://www.posimir.com).



View original content: [https://www.prnewswire.com/news-releases/durect-corporation-to-announce-second-quarter-](https://www.prnewswire.com/news-releases/durect-corporation-to-announce-second-quarter-2021-financial-results-and-provide-business-update-on-july-29-301339260.html)

[2021-financial-results-and-provide-business-update-on-july-29-301339260.html](https://www.prnewswire.com/news-releases/durect-corporation-to-announce-second-quarter-2021-financial-results-and-provide-business-update-on-july-29-301339260.html)



SOURCE DURECT Corporation

Corporate Contact: Mike Arenberg, DURECT Chief Financial Officer, +1-408-346-1052, [mike.arenberg@durect.com](mailto:mike.arenberg@durect.com); Media  
Contact: Mónica Rouco Molina, PhD, LifeSci Communications, [mroucomolina@lifescicomms.com](mailto:mroucomolina@lifescicomms.com)